David A. Kessler | Academic Influence

David A. Kessler's AcademicInfluence.com Rankings

David A. Kessler

Medical

#75

World Rank

#131

Historical Rank

#38

USA Rank

Public Health

#16

World Rank

#17

Historical Rank

#9

USA Rank

medical Degrees

David A. Kessler

Philosophy

#4720

World Rank

#7340

Historical Rank

#1327

USA Rank

Logic

#8480

World Rank

#10619

Historical Rank

#1407

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

David A. Kessler's Degrees

Doctorate Medicine Harvard University
Doctorate Law University of Chicago

Why Is David A. Kessler Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Aaron Kessler is an American pediatrician, attorney, author, and administrator serving as Chief Science Officer of the White House COVID-19 Response Team since 2021. Kessler was the commissioner of the Food and Drug Administration from November 8, 1990, to February 28, 1997. He co-chaired the Biden-Harris transition’s COVID-19 Advisory Board from November 2020 to January 2021 and was the head of Operation Warp Speed, the U.S. government program to accelerate the development of COVID-19 vaccines and other treatments, from January to February 2021.

(See a Problem?)

David A. Kessler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

FDA regulation of stem-cell-based therapies. (2006) (384)
Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. (1993) (282)
The basis of the FDA's decision on breast implants. (1992) (265)
Department of Health and Human Services Food and Drug Administration Food Standards: Amendment of Standards of Identity for Enriched Grain Products to Require Addition of Folic Acid (237)
Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. (1993) (234)
Therapeutic-class wars--drug promotion in a competitive marketplace. (1994) (162)
Demand Effects of Recent Changes in Prescription Drug Promotion (2003) (137)
Regulation of somatic-cell therapy and gene therapy by the food and drug administration. (1993) (127)
Nicotine addiction in young people. (1995) (124)
The safety of foods developed by biotechnology. (1992) (112)
Cancer and herbs. (2000) (100)
The federal regulation of prescription drug advertising and promotion. (1990) (92)
Nicotine addiction: a pediatric disease. (1997) (91)
Communicating with patients about their medications. (1991) (80)
A question of intent : a great American battle with a deadly industry (2001) (73)
The Food and Drug Administration's regulation of tobacco products. (1996) (72)
The regulation of investigational drugs. (1989) (66)
The End of Overeating: Taking Control of the Insatiable American Appetite (2009) (62)
Drug Promotion and Scientific Exchange (1991) (50)
Addressing the problem of misleading advertising. (1992) (49)
The Federal regulation of medical devices. (1987) (39)
Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. (1994) (37)
Statement on nicotine-containing cigarettes (1994) (36)
The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco. (1997) (33)
Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan. (1996) (32)
A call for higher standards for breast implants. (1993) (31)
Faster evaluation of vital drugs. (1995) (26)
Drug promotion and scientific exchange. The role of the clinical investigator. (1991) (24)
Beyond the tobacco settlement. (2001) (23)
The control and manipulation of nicotine in cigarettes (1994) (22)
Alcohol Marketing and Youth: The Challenge for Public Health (2005) (22)
Toward more comprehensive food labeling. (2014) (20)
Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. (1994) (19)
Direct-to-Consumer Advertising: Is It Too Late to Manage the Risks? (2007) (19)
The evolution of national nutrition policy. (1995) (19)
Developing the "Nutrition Facts" Food Label (2003) (19)
Food safety: revising the statute. (1984) (18)
The Federal regulation of food labeling. Promoting foods to prevent disease. (1989) (17)
Final report of the Advisory Committee on Tobacco Policy and Public Health. (1997) (16)
MEDWatch: the new FDA medical products reporting program. (1993) (14)
The tobacco settlement. (1997) (12)
Reinventing American tobacco policy: sounding the medical community's voice. (1998) (11)
A challenge for American pharmacists. (1992) (8)
The end of overeating : taking control of our insatiable appetite (2010) (8)
The Food and Drug Administration's rule on tobacco: blending science and Law. (1997) (5)
Building a better food label (1991) (4)
Foodborne illness in the 1990s. (1993) (4)
MedWatch: FDA's New Medical Products Reporting Program (1993) (3)
Silicone Gel Breast Implants-Reply (1994) (2)
A century on Spring Street (1998) (2)
Changing the culture of medicine: the FDA's MEDWatch program (1993) (2)
In memoriam ☆: Alvan R. Feinstein, MD (1925–2001) (2002) (2)
Implementing the Anticancer Clauses of the Food, Drug and Cosmetic Act (1977) (2)
Hastings lecture, December 10, 1993, Rockville, Maryland, U.S.A. (1994) (2)
THE FOOD AND DRUG ADMINISTRATION AND ITS PROBLEMS. AUTHOR'S REPLIES (1992) (2)
Applying a Public Health Approach to Decrease Obesity in the United States (2003) (1)
THE BEST OF THE PAST: TRADITIONAL, SUSTAINABLE AGRICULTURE IN PRINCE (1989) (1)
The FDA and Drug Marketing Expenditures-Reply (1991) (1)
Remarks by the Commissioner (1991) (1)
Remarks by the Commissioner. FDA. (1991) (1)
Symposium Address: Regulation of Tobacco: Health Promotion and Cancer Prevention (1999) (1)
FDA's Kessler: a prescription for change. Interview by Marlene Z. Bloom. (1991) (1)
USING MEDWATCH: A BETTER WAY TO REPORT ADVERSE EVENTS (1993) (1)
FOODBORNE ILLNESS IN THE 1990S. AUTHOR'S REPLY (1993) (0)
THE FDA AND DRUG MARKETING EXPENDITURES. AUTHOR'S REPLY (1991) (0)
David A. Kessler Named New Dean of UCSF School of Medicine (2003) (0)
Prescription for change: an interview with FDA Commissioner Dr. David Kessler. (1992) (0)
How to End the Tobacco Epidemic What Tobacco Control Strategy Should be Used ? (2013) (0)
Remarks by the Commissioner of Food and Drugs at the twentieth anniversary celebration of the 1976 Medical Device Amendments. (1996) (0)
POSTMARKETING SURVEILLANCE : BEYOND MEDWATCH. AUTHOR REPLY (1993) (0)
Postmarketing Surveillance: Beyond medWatch-Reply (1993) (0)
Remarks by the Commissioner of Food and Drugs. (1995) (0)
Flow control valve for a fuel system (1989) (0)
Like the back of my hand: Journal of a Prince Edward Island naturalist, Geoff Hogan (1953-1992) (1994) (0)
MED W ATCH IMPROVING PATIENT CARE BY REPORTING PROBLEMS WITH MEDICAL DEVICES (1997) (0)
A tribute to C. Everett Koop (2013) (0)
Written evidence submitted by Blue Skies China (ECG0086) Fun question for the panel (2018) (0)
Remarks by the Commissioner of Food and Drugs. (1997) (0)
FDA's revitalization of medical device review and regulation. (1994) (0)
MEDWatch: the new FDA medical products reporting program. (1993) (0)
321: Motorcycle Helmet Use in the Dominican Republic (2007) (0)
The bend in the road (2000) (0)
The bend in the road: An invitation to the world and works of L. M. Montgomery (2000) (0)
Remarks by the Commissioner of Food and Drugs. (1996) (0)
On Day 24 the Mountain Moved Inside (2011) (0)

This paper list is powered by the following services:

Other Resources About David A. Kessler

en.wikipedia.org

What Schools Are Affiliated With David A. Kessler?

David A. Kessler is affiliated with the following schools:

Image Attributions

Image Source for David A. Kessler